1
|
Tyleckova J, Hrabakova R, Mairychova K, Halada P, Radova L, Dzubak P, Hajduch M, Gadher SJ, Kovarova H. Cancer cell response to anthracyclines effects: mysteries of the hidden proteins associated with these drugs. Int J Mol Sci 2012; 13:15536-64. [PMID: 23443080 PMCID: PMC3546648 DOI: 10.3390/ijms131215536] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2012] [Revised: 10/26/2012] [Accepted: 11/07/2012] [Indexed: 12/15/2022] Open
Abstract
A comprehensive proteome map of T-lymphoblastic leukemia cells and its alterations after daunorubicin, doxorubicin and mitoxantrone treatments was monitored and evaluated either by paired comparison with relevant untreated control and using multivariate classification of treated and untreated samples. With the main focus on early time intervals when the influence of apoptosis is minimized, we found significantly different levels of proteins, which corresponded to 1%–2% of the total amount of protein spots detected. According to Gene Ontology classification of biological processes, the highest representation of identified proteins for all three drugs belong to metabolic processes of proteins and nucleic acids and cellular processes, mainly cytoskeleton organisation and ubiquitin-proteasome pathway. Importantly, we observed significant proportion of changes in proteins involved in the generation of precursor metabolites and energy typical for daunorubicin, transport proteins participating in response to doxorubicin and a group of proteins of immune system characterising response to mitoxantrone. Both a paired comparison and the multivariate evaluation of quantitative data revealed daunorubicin as a distinct member of the group of anthracycline/anthracenedione drugs. A combination of identified drug specific protein changes, which may help to explain anti-cancer activity, together with the benefit of blocking activation of adaptive cancer pathways, presents important approaches to improving treatment outcomes in cancer.
Collapse
Affiliation(s)
- Jirina Tyleckova
- Institute of Animal Physiology and Genetics AS CR, v.v.i., 277 21 Libechov, Czech Republic; E-Mails: (J.T.); (R.H.); (K.M.)
| | - Rita Hrabakova
- Institute of Animal Physiology and Genetics AS CR, v.v.i., 277 21 Libechov, Czech Republic; E-Mails: (J.T.); (R.H.); (K.M.)
| | - Katerina Mairychova
- Institute of Animal Physiology and Genetics AS CR, v.v.i., 277 21 Libechov, Czech Republic; E-Mails: (J.T.); (R.H.); (K.M.)
| | - Petr Halada
- Institute of Microbiology AS CR, v.v.i., 142 20 Prague, Czech Republic; E-Mail:
| | - Lenka Radova
- Laboratory of Experimental Medicine, Institute of Translational and Molecular Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 775 15 Olomouc, Czech Republic; E-Mails: (L.R.); (P.D.); (M.H.)
| | - Petr Dzubak
- Laboratory of Experimental Medicine, Institute of Translational and Molecular Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 775 15 Olomouc, Czech Republic; E-Mails: (L.R.); (P.D.); (M.H.)
| | - Marian Hajduch
- Laboratory of Experimental Medicine, Institute of Translational and Molecular Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 775 15 Olomouc, Czech Republic; E-Mails: (L.R.); (P.D.); (M.H.)
| | | | - Hana Kovarova
- Institute of Animal Physiology and Genetics AS CR, v.v.i., 277 21 Libechov, Czech Republic; E-Mails: (J.T.); (R.H.); (K.M.)
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +420-315-639-582; Fax: +420-315-639-510
| |
Collapse
|
2
|
Alvergnas M, Rouleau A, Lucchi G, Heyd B, Ducoroy P, Richert L, Martin H. Proteomic mapping of bezafibrate-treated human hepatocytes in primary culture using two-dimensional liquid chromatography. Toxicol Lett 2011; 201:123-9. [DOI: 10.1016/j.toxlet.2010.12.015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2010] [Revised: 12/17/2010] [Accepted: 12/21/2010] [Indexed: 10/25/2022]
|
3
|
Skalnikova H, Martinkova J, Hrabakova R, Halada P, Dziechciarkova M, Hajduch M, Gadher SJ, Hammar A, Enetoft D, Ekefjard A, Forsstrom-Olsson O, Kovarova H. Cancer drug-resistance and a look at specific proteins: Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and HSP70/90 organizing protein in proteomics clinical application. J Proteome Res 2010; 10:404-15. [PMID: 21067243 DOI: 10.1021/pr100468w] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Resistance to anti-cancer drugs is a well recognized problem and very often it is responsible for failure of the cancer treatment. In this study, the proteome alterations associated with the development of acquired resistance to cyclin-depedent kinases inhibitor bohemine, a promising anti-cancer drug, were analyzed with the primary aim of identifying potential targets of resistance within the cell that could pave a way to selective elimination of specific resistant cell types. A model of parental susceptible CEM T-lymphoblastic leukemia cells and its resistant counterpart CEM-BOH was used and advanced 2-D liquid chromatography was applied to fractionate cellular proteins. Differentially expressed identified proteins were further verified using immunoblotting and immunohistochemistry. Our study has revealed that Rho GDP-dissociation inhibitor 2, Y-box binding protein 1, and the HSP70/90 organizing protein have a critical role to play in resistance to cyclin-depedent kinases inhibitor. The results indicated not only that quantitative protein changes play an important role in drug-resistance, but also that there are various other parameters such as truncation, post-translational modification(s), and subcellular localization of selected proteins. Furthermore, these proteins were validated for their roles in drug resistance using different cell lines resistant to diverse representatives of anti-cancer drugs such as vincristine and daunorubicin.
Collapse
Affiliation(s)
- Helena Skalnikova
- Institute of Animal Physiology and Genetics AS CR, vvi, Libechov, Czech Republic
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Moseley FL, Bicknell KA, Marber MS, Brooks G. The use of proteomics to identify novel therapeutic targets for the treatment of disease. J Pharm Pharmacol 2010; 59:609-28. [PMID: 17524226 DOI: 10.1211/jpp.59.5.0001] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Abstract
The completion of the Human Genome Project has revealed a multitude of potential avenues for the identification of therapeutic targets. Extensive sequence information enables the identification of novel genes but does not facilitate a thorough understanding of how changes in gene expression control the molecular mechanisms underlying the development and regulation of a cell or the progression of disease. Proteomics encompasses the study of proteins expressed by a population of cells, and evaluates changes in protein expression, post-translational modifications, protein interactions, protein structure and splice variants, all of which are imperative for a complete understanding of protein function within the cell. From the outset, proteomics has been used to compare the protein profiles of cells in healthy and diseased states and as such can be used to identify proteins associated with disease development and progression. These candidate proteins might provide novel targets for new therapeutic agents or aid the development of assays for disease biomarkers. This review provides an overview of the current proteomic techniques available and focuses on their application in the search for novel therapeutic targets for the treatment of disease.
Collapse
Affiliation(s)
- Fleur L Moseley
- School of Pharmacy, The University of Reading, Whiteknights, Reading, Berkshire, RG6 6AP, UK
| | | | | | | |
Collapse
|
5
|
Jarkovska K, Martinkova J, Liskova L, Halada P, Moos J, Rezabek K, Gadher SJ, Kovarova H. Proteome Mining of Human Follicular Fluid Reveals a Crucial Role of Complement Cascade and Key Biological Pathways in Women Undergoing in Vitro Fertilization. J Proteome Res 2010; 9:1289-301. [DOI: 10.1021/pr900802u] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Karla Jarkovska
- Institute of Animal Physiology and Genetics AS CR, v.v.i., Libechov, Czech Republic, Institute of Microbiology AS CR, v.v.i., Prague, Czech Republic, Assisted Reproduction Centre, Department of Obstetrics and Gynecology, General Teaching Hospital, Prague, Czech Republic, Sigma-Aldrich spol. s.r.o., Prague, Czech Republic, and Millipore Bioscience, 15 Research Park Drive, St. Charles, Missouri 63304
| | - Jirina Martinkova
- Institute of Animal Physiology and Genetics AS CR, v.v.i., Libechov, Czech Republic, Institute of Microbiology AS CR, v.v.i., Prague, Czech Republic, Assisted Reproduction Centre, Department of Obstetrics and Gynecology, General Teaching Hospital, Prague, Czech Republic, Sigma-Aldrich spol. s.r.o., Prague, Czech Republic, and Millipore Bioscience, 15 Research Park Drive, St. Charles, Missouri 63304
| | - Lucie Liskova
- Institute of Animal Physiology and Genetics AS CR, v.v.i., Libechov, Czech Republic, Institute of Microbiology AS CR, v.v.i., Prague, Czech Republic, Assisted Reproduction Centre, Department of Obstetrics and Gynecology, General Teaching Hospital, Prague, Czech Republic, Sigma-Aldrich spol. s.r.o., Prague, Czech Republic, and Millipore Bioscience, 15 Research Park Drive, St. Charles, Missouri 63304
| | - Petr Halada
- Institute of Animal Physiology and Genetics AS CR, v.v.i., Libechov, Czech Republic, Institute of Microbiology AS CR, v.v.i., Prague, Czech Republic, Assisted Reproduction Centre, Department of Obstetrics and Gynecology, General Teaching Hospital, Prague, Czech Republic, Sigma-Aldrich spol. s.r.o., Prague, Czech Republic, and Millipore Bioscience, 15 Research Park Drive, St. Charles, Missouri 63304
| | - Jiri Moos
- Institute of Animal Physiology and Genetics AS CR, v.v.i., Libechov, Czech Republic, Institute of Microbiology AS CR, v.v.i., Prague, Czech Republic, Assisted Reproduction Centre, Department of Obstetrics and Gynecology, General Teaching Hospital, Prague, Czech Republic, Sigma-Aldrich spol. s.r.o., Prague, Czech Republic, and Millipore Bioscience, 15 Research Park Drive, St. Charles, Missouri 63304
| | - Karel Rezabek
- Institute of Animal Physiology and Genetics AS CR, v.v.i., Libechov, Czech Republic, Institute of Microbiology AS CR, v.v.i., Prague, Czech Republic, Assisted Reproduction Centre, Department of Obstetrics and Gynecology, General Teaching Hospital, Prague, Czech Republic, Sigma-Aldrich spol. s.r.o., Prague, Czech Republic, and Millipore Bioscience, 15 Research Park Drive, St. Charles, Missouri 63304
| | - Suresh Jivan Gadher
- Institute of Animal Physiology and Genetics AS CR, v.v.i., Libechov, Czech Republic, Institute of Microbiology AS CR, v.v.i., Prague, Czech Republic, Assisted Reproduction Centre, Department of Obstetrics and Gynecology, General Teaching Hospital, Prague, Czech Republic, Sigma-Aldrich spol. s.r.o., Prague, Czech Republic, and Millipore Bioscience, 15 Research Park Drive, St. Charles, Missouri 63304
| | - Hana Kovarova
- Institute of Animal Physiology and Genetics AS CR, v.v.i., Libechov, Czech Republic, Institute of Microbiology AS CR, v.v.i., Prague, Czech Republic, Assisted Reproduction Centre, Department of Obstetrics and Gynecology, General Teaching Hospital, Prague, Czech Republic, Sigma-Aldrich spol. s.r.o., Prague, Czech Republic, and Millipore Bioscience, 15 Research Park Drive, St. Charles, Missouri 63304
| |
Collapse
|
6
|
Matharoo-Ball B, Miles AK, Creaser CS, Ball G, Rees R. Serum biomarker profiling in cancer studies: a question of standardisation? Vet Comp Oncol 2009; 6:224-47. [PMID: 19178682 DOI: 10.1111/j.1476-5829.2008.00171.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Companion animals are exposed to similar environmental conditions and carcinogens as humans. In some animal cancers, there also appears to be the same genetic changes associated as in humans. However, little work has been carried out in cancer biomarker identification in animals. The recent dramatic advances in molecular medicine, genomics, proteomics and translational research will allow biomarker identification, which may provide the best strategies for veterinarians and clinicians to combat disease by early diagnosis and administration of effective treatments. Proteomics may have important applications in cancer diagnosis, prognosis and predictive clinical outcome that could directly change clinical practice by affecting critical elemen-ts of care and management. This review summarizes the advances in proteomics that has propelled us to this exciting age of clinical proteomics, and highlights the future work that is required for this to become a reality. In this review, we will discuss the available proteomic technologies and their limitations, and highlight the key areas of research and how they have been used to discover cancer biomarkers. The principles described here are equally applicable to human and animal disease, but implementation of 'omic' technologies requires stringent guidelines for collection of clinical material, the application of analytical techniques and interpretation of the data.
Collapse
Affiliation(s)
- B Matharoo-Ball
- The John Van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, UK
| | | | | | | | | |
Collapse
|
7
|
Gu F, Shi J, Wen Y, Fan H, Hu J, Hu Y, Zhao Z. Translational responses of NR2B overexpression in the cerebral cortex of transgenic mice: A liquid chromatography-based proteomic approach. Brain Res 2009; 1250:1-13. [DOI: 10.1016/j.brainres.2008.10.039] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2008] [Revised: 08/01/2008] [Accepted: 10/12/2008] [Indexed: 10/21/2022]
|
8
|
Wang Y, Chiu JF, He QY. Genomics and Proteomics in Drug Design and Discovery. Pharmacology 2009. [DOI: 10.1016/b978-0-12-369521-5.00020-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
Patwa TH, Wang Y, Miller FR, Goodison S, Pennathur S, Barder TJ, Lubman DM. A novel phosphoprotein analysis scheme for assessing changes in premalignant and malignant breast cell lines using 2D liquid separations, protein microarrays and tandem mass spectrometry. Proteomics Clin Appl 2008; 3:51-66. [PMID: 19194518 DOI: 10.1002/prca.200800097] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
An analysis of phosphorylation changes that occur during cancer progression would provide insights into the molecular pathways responsible for a malignant phenotype. In this study we employed a novel coupling of 2D-liquid separations and protein microarray technology to reveal changes in phosphoprotein status between premalignant (AT1) and malignant (CA1a) cell lines derived from the human MCF10A breast cell lines. Intact proteins were first separated according to their isoelectric point and hydrophobicities, then arrayed on SuperAmine glass slides. Phosphoproteins were detected using the universal, inorganic phospho-sensor dye, ProQ Diamond. Using this dye, out of 140 spots that were positive for phosphorylation, a total of 85 differentially expressed spots were detected over a pH range of 7.2 to 4.0. Proteins were identified and their peptides sequenced by mass spectrometry. The strategy enabled the identification of 75 differentially expressed phosphoproteins, from which 51 phosphorylation sites in 27 unique proteins were confirmed. Interestingly, the majority of differentially expressed phosphorylated proteins observed were nuclear proteins. Three regulators of apoptosis, Bad, Bax and Acinus, were also differentially phosphorylated in the two cell lines. Further development of this strategy will facilitate an understanding of the mechanisms involved in malignancy progression and other disease-related phenotypes.
Collapse
Affiliation(s)
- Tasneem H Patwa
- Department of Chemistry, University of Michigan, Ann Arbor, MI, USA 48109-0656
| | | | | | | | | | | | | |
Collapse
|
10
|
Saldanha RG, Xu N, Molloy MP, Veal DA, Baker MS. Differential proteome expression associated with urokinase plasminogen activator receptor (uPAR) suppression in malignant epithelial cancer. J Proteome Res 2008; 7:4792-806. [PMID: 18808175 DOI: 10.1021/pr800357h] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Dysregulation of the plasminogen activation cascade is a prototypic feature in many malignant epithelial cancers. Principally, this is thought to occur through activation of overexpressed urokinase plasminogen activator (uPA) concomitant with binding to its high specificity cell surface receptor urokinase plasminogen activator receptor (uPAR). Up-regulation of uPA and uPAR in cancer appears to potentiate the malignant phenotype, either (i) directly by triggering plasmin-mediated degradation or activation of uPA's or plasmin's proteolytic targets (e.g., extracellular matrix zymogen proteases or nascent growth factors) or indirectly by simultaneously altering a range of downstream functions including signal transduction pathways ( Romer, J. ; Nielsen, B. S. ; Ploug, M. The urokinase receptor as a potential target in cancer therapy Curr. Pharm. Des. 2004, 10 ( 19), 235976 ). Because many malignant epithelial cancers express high levels of uPAR, uPA or other components of the plasminogen activation cascade and because these are often associated with poor prognosis, characterizing how uPAR changes the downstream cellular "proteome" is fundamental to understanding any role in cancer. This study describes a carefully designed proteomic study of the effects of antisense uPAR suppression in a previously studied colon cancer cell line (HCT116). The study utilized replicate 2DE gels and two independent gel image analysis software packages to confidently identify 64 proteins whose expression levels changed (by > or =2 fold) coincident with a moderate ( approximately 40%) suppression of cell-surface uPAR. Not surprisingly, many of the altered proteins have previously been implicated in the regulation of tumor progression (e.g., p53 tumor suppressor protein and c-myc oncogene protein among many others). In addition, through a combination of proteomics and immunological methods, this study demonstrates that stathmin 1alpha, a cytoskeletal protein implicated in tumor progression, undergoes a basic isoelectric point shift (p I) following uPAR suppression, suggesting that post-translational modification of stathmin occur secondary to uPAR suppression. Overall, these results shed new light on the molecular mechanisms involved in uPAR signaling and how it may promulgate the malignant phenotype.
Collapse
Affiliation(s)
- Rohit G Saldanha
- Department of Chemistry and Biomolecular Sciences and Australian Proteome Analysis Facility, Macquarie University, Sydney, NSW 2109, Australia
| | | | | | | | | |
Collapse
|
11
|
Hajduch M, Skalnikova H, Halada P, Vydra D, Dzubak P, Dziechciarkova M, Strnad M, Radioch D, Gadher SJ, Kovarova H. Cyclin-Dependent Kinase Inhibitors and Cancer: Usefulness of Proteomic Approaches in Assessment of the Molecular Mechanisms and Efficacy of Novel Therapeutics. Clin Proteomics 2008. [DOI: 10.1002/9783527622153.ch13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
|
12
|
Skalnikova H, Rehulka P, Chmelik J, Martinkova J, Zilvarova M, Gadher SJ, Kovarova H. Relative quantitation of proteins fractionated by the ProteomeLab™ PF 2D system using isobaric tags for relative and absolute quantitation (iTRAQ). Anal Bioanal Chem 2007; 389:1639-45. [PMID: 17724578 DOI: 10.1007/s00216-007-1547-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2007] [Revised: 08/03/2007] [Accepted: 08/06/2007] [Indexed: 10/22/2022]
Abstract
We describe an optimised protocol for application of isobaric tags for relative and absolute quantitation (iTRAQ) and tandem mass spectrometry to obtain relative quantitative data from peptides derived from tryptic digestions of proteins fractionated by using the 2D liquid-phase ProteomeLab PF 2D technique. This methodology is suitable for the quantitation of proteins from a pool of co-eluting proteins which are often difficult to identify for the purpose of candidate protein selection for biologically relevant qualitative/quantitative changes under experimental conditions or in disease states. iTRAQ quantitation also facilitates the possibility of result to result comparison using other methodologies such as UV protein quantitation via the ProteomeLab PF 2D technique. The optimised protocol outlined here allows relative quantitation by MALDI-TOF/TOF mass spectrometry with high sensitivity and without the need to perform 2D HPLC separation of labelled peptides. The overall outcome is the simplification in the data complexity and the ease of use of the labelling protocol.
Collapse
Affiliation(s)
- Helena Skalnikova
- Institute of Animal Physiology and Genetics, Academy of Sciences of Czech Republic, Rumburska 89, 277 21 Libechov, Czech Republic
| | | | | | | | | | | | | |
Collapse
|
13
|
Gunther NW, Nuñez A, Fortis L, Solaiman DKY. Proteomic based investigation of rhamnolipid production by Pseudomonas chlororaphis strain NRRL B-30761. J Ind Microbiol Biotechnol 2006; 33:914-20. [PMID: 16964509 DOI: 10.1007/s10295-006-0169-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2005] [Accepted: 02/04/2006] [Indexed: 10/24/2022]
Abstract
We recently reported that a strain of the non-pathogenic bacterial species Pseudomonas chlororaphis was capable of producing the biosurfactant molecule, rhamnolipids. Previous to this report the organisms known to produce rhamnolipids were almost exclusively pathogens. The newly described P. chlororaphis strain produced rhamnolipids at room temperature in static minimal media, as opposed to previous reports of rhamnolipid production which occurred at elevated temperatures with mechanical agitation. The non-pathogenic nature and energy conserving production conditions make the P. chlororaphis strain an attractive candidate for commercial rhamnolipid production. However, little characterization of molecular/biochemical processes in P. chlororaphis have been reported. In order to achieve a greater understanding of the process by which P. chlororaphis produces rhamnolipids, a survey of proteins differentially expressed during rhamnolipid production was performed. Separation and measurement of the bacteria's proteome was achieved using Beckman Coulter's Proteome Lab PF2D packed column-based protein fractionation system. Statistical analysis of the data identified differentially expressed proteins and known orthologues of those proteins were identified using an AB 4700 Proteomics Analyzer mass spectrometer system. A list of proteins differentially expressed by P. chlororaphis strain NRRL B-30761 during rhamnolipid production was generated, and confirmed through a repetition of the entire separation process.
Collapse
Affiliation(s)
- Nereus W Gunther
- Agricultural Research Service, Eastern Regional Research Center, U.S. Department of Agriculture, 600 East Mermaid Lane, Wyndmoor, PA 19038-8598, USA
| | | | | | | |
Collapse
|
14
|
Lin WY, Song CY, Pan TM. Proteomic analysis of Caco-2 cells treated with monacolin K. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2006; 54:6192-200. [PMID: 16910707 DOI: 10.1021/jf061060c] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Monascus species is an important traditional fermentation fungus used on food. Monacolin K (a secondary metabolite of Monascus, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase) in inhibition of mevalonate synthesis may result in reductions of isoprenoid prenylation in cells. Impairment of protein isoprenoid prenylation has been related to anticancer effect in cancer cells. As a functional food for Monascus, however, the molecular mechanisms responsible for the anti-proliferate effect of monacolin K in cancer cells are not clear. We used proteomic analysis by two-dimensional gel electrophoresis, matrix-assisted laser desorption ionization time-of-flight/time-of-flight mass spectrometry (MALDI-TOF/TOF MS), tandem mass spectrometry (MS/MS), and database interrogation to separate and identify the proteins of Caco-2 cells treated with monacolin K. The results showed that monacolin K inhibited the proliferation of Caco-2 cells in a dose-dependent manner. The identified proteins in proteomic analysis included anti-oxidation enzymes related to reactive oxygen species stress, cytoskeleton proteins, glycolytic enzymes, and enzymes involved in mediating protein interactions. Furthermore, glutathione S-transferase P 1 and cytoskeleton-8, -18, and -19 revealed a down-regulation in a dose-dependent manner in exposure of Caco-2 cells to monacolin K.
Collapse
Affiliation(s)
- Wun-Yuan Lin
- Department of Food Science, Nutrition and Nutraceutical Biotechnology, Shih Chien University, Taipei, Taiwan, Republic of China
| | | | | |
Collapse
|